Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions
AssigneeOsteologix A/S
InventorsChristian Hansen, Henrik Nilsson, Stephan Christgau, Jens E.T. Andersen
Life of this patent
Estimating the term…
Abstract
Compounds and pharmaceutical compositions for use in the treatment and/or prophylaxis of cartilage and/or bone conditions and for methods of treating such condition. The compounds are salts of strontium that have a water-solubility of from about 1 g/l to about 100 g/l at room temperature, especially amino acid salts of strontium or dicarboxylic acid salts of strontium. Examples of novel water-soluble strontium salts are e.g. strontium glutamate and strontium alpha-ketoglutarate. The present invention also relates to an improved method for preparing the strontium salt of glutamic acid.
Claims80
A method for the treatment of a bone disease in a mammal in need thereof, wherein the bone disease is osteoporosis or osteopenia, the method comprising administering a therapeutically effective amount of strontium malonate to the mammal.
A method for the treatment of a bone disease in a subject, wherein the bone disease is osteoporosis or osteopenia, comprising administering a strontium salt to the subject, wherein the strontium salt provides a maximum plasma concentration of strontium from about 4 to about 24 hours after administration to said subject, wherein the strontium salt is strontium malonate.
A method for the treatment of a bone disease in a subject, wherein the bone disease is osteoporosis or osteopenia, comprising administering a strontium salt to the subject, wherein the strontium salt provides a maximum plasma concentration of strontium from about 5.5 to about 24 hours after administration to said subject, wherein the strontium salt is strontium malonate.
A method for the treatment of a bone disease in a subject, wherein the bone disease is osteoporosis or osteopenia, comprising administering to the subject a pharmaceutical composition comprising strontium malonate and one or more pharmaceutically acceptable excipients, wherein the pharmaceutical composition provides a maximum plasma concentration of strontium from about 5.5 to about 24 hours after administration to said subject.
A method for the treatment of a bone disease in a subject, wherein the bone disease is osteoporosis or osteopenia, comprising administering to the subject a pharmaceutical composition comprising strontium malonate and one or more pharmaceutically acceptable excipients, wherein the pharmaceutical composition provides a maximum plasma concentration of strontium from about 4 to about 24 hours after administration to said subject.
A method for the treatment of a bone disease in a subject, wherein the bone disease is osteoporosis or osteopenia, comprising administering to the subject a pharmaceutical composition comprising strontium malonate and one or more pharmaceutically acceptable excipients to provide a steady state plasma concentration of from about 5 to about 50 mg/L of strontium in said subject after repeated administration through steady state conditions.
Dependencies are inferred from the claim text.